Synthetic Drugs

March 18, 2024 | Fact Sheets, Novel Psychoactive Substances, Opioids, Public Safety, Stimulants, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet,  examines xylazine, a powerful veterinary sedative increasingly appearing as an adulterant in heroin and fentanyl mixtures in the U.S., particularly since 2020. Xylazine has a chemical structure similar to compounds called phenothiazines and operates by decreasing the release of norepinephrine and dopamine in the central nervous system, resulting in analgesia, sedation, and muscle relaxation. Xylazine intoxication can result in central nervous system depression, low blood pressure, and slow heart rate. Respiratory depression can also occur, which increases the risk of overdose when combined with opioid-induced respiratory depression. ...

October 31, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet examines bromazolam, a novel benzodiazepine that is structurally related to alprazolam (Xanax), which has been a Schedule IV controlled substance in the U.S. since November 1981. Bromazolam is typically found in tablet or powder form and sold mainly via online drug markets under its own name or as “XLI-268.” It has been found mixed with opioids, including fentanyl, and in counterfeit Xanax pills. There is not much information about the illicit use of bromazolam and its effects on the human body in scientific literature, so most of the information currently available about the substance is anecdotal. ...

September 18, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet examines nitazenes, a group of synthetic opioids more powerful than fentanyl. Scientists developed nitazenes in the 1950s as analgesics, but the U.S. Food and Drug Administration never approved the compounds for therapeutic use....

June 6, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet examines isotonitazene, a synthetic opioid, recently classified as a Schedule I controlled substance under the federal Controlled Substances Act, that is 500 times more potent than morphine. Experts believe that isotonitazene is mixed into other drugs to make the combined product more potent and profitable for the dealer. Law enforcement reports encountering isotonitazene both in powder form, which appears yellow, brown, or off-white in color, and also as counterfeit pills. Based on the most recent data available as of June 2021, there have been more than 250 reported fatalities in the U.S. involving isotonitazene....

April 24, 2023 | Alcohol, Controlled Substances, Fentanyl, Marijuana, Methamphetamine, Opioids, Prescription Drugs, Public Health, Reports & Studies, Stimulants, Substance Misuse, Synthetic Drugs

The purpose of this report was to assess immediate and sustained changes in overall illicit substance ingestion rates among children younger than six before and during the COVID-19 pandemic and to examine changes by substance type, including amphetamines, benzodiazepines, cannabis, cocaine, ethanol, and, opioids. Researchers concluded that there was a sustained increase in illicit substance ingestion during the pandemic and that additional studies are needed to contextualize these findings in the setting of pandemic-related stress....

January 6, 2023 | Controlled Substances, Fact Sheets, Fentanyl, Kratom, Marijuana, Methamphetamine, Novel Psychoactive Substances, Opioids, Prescription Drugs, Stimulants, Substance Misuse, Synthetic Drugs

Millions of people throughout the world use social media platforms (or “apps”) that provide an easy avenue to reach a large number of people. Legitimate businesses are not the only ones to use social media apps as a marketing tool. In recent years, drug dealers have turned to such apps to solicit buyers and arrange sales. This fact sheet examines the growing use of social media, by drug suppliers, to surreptitiously advertise to a wide audience, by using apps that offer encrypted or disappearing messages....

September 1, 2022 | Fact Sheets, Novel Psychoactive Substances, Opioids, Public Safety, Stimulants, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet,  examines pyro, a relatively new high potency synthetic opioid increasing in prevalence in the U.S. Pyro belongs to an opioid subclass of NPS called 2-benezylbenzimidazoles, or nitazenes, and is structurally similar to etonitazene, a synthetic opioid that is nationally and internationally controlled. N-pyrrolidino etonitazene is not described or mentioned in any medical literature or patents, meaning that it is a truly “novel” NPS and likely developed independently from the pharmaceutical industry. Researchers believe that N-pyrrolidino etonitazene is coming to the U.S. via purchases on the dark web and is likely being produced in China. N-pyrrolidino etonitazene can be found in powder form or pressed into pills to resemble other substances. Studies estimate that N-pyrrolidino etonitazene is over 800 times more potent than morphine and 20-40 times more potent than fentanyl. Like other opioids, N-pyrrolidino etonitazene use can potentially cause fatal respiratory depression in the person ingesting the drug. However, because...